01—Abstract
Summary
Summary of the 8-K filed August 17, 2026. Cited figures are marked; the original filing is the authoritative source.
ResMed Inc. (NYSE: RMD) filed this Current Report on Form 8-K dated August 17, 2026, disclosing two governance and accounting changes.
First, under Item 4.01, the company dismissed KPMG LLP as its independent registered public accounting firm effective August 13, 2026, and appointed PricewaterhouseCoopers LLP as its new auditor, subject to completion of PwC's standard client acceptance procedures, for the fiscal year ending June 30, 2027. The filing states that KPMG's reports on the fiscal 2026 and 2025 consolidated financial statements contained no adverse opinion or disclaimer and were not qualified or modified, and that there were no disagreements or reportable events during the relevant periods. KPMG's letter to the SEC is referenced as Exhibit 16.1.
Second, under Item 5.02, director Ronald Taylor informed the Board on August 13, 2026 that he will not stand for election at the 2026 Annual Meeting, expected to be held November 18, 2026, and will retire from the Board at that time. The filing states his decision is not due to any disagreement with the company on its operations, policies or practices. The Board appointed Carol Burt, who chairs the Nominating and Governance Committee, as lead director effective November 15, 2026.
Per the attached press release (Exhibit 99.1), Taylor joined the Board in 2005 and had served as Lead Director since 2013. The filing describes a competitive review process by the Audit Committee for selecting the new auditor. It does not state a reason for the auditor change beyond that review, and it contains no financial results or operating figures.
02—Key points
Key Highlights
- Auditor change: KPMG LLP was dismissed effective August 13, 2026, and PricewaterhouseCoopers LLP was appointed for the fiscal year ending June 30, 2027, subject to standard client acceptance procedures.
- No adverse findings disclosed: The filing states KPMG's reports on fiscal 2026 and 2025 financial statements carried no adverse opinion, disclaimer, or qualification, and that no disagreements or reportable events occurred.
- Audit Committee process: The change followed a competitive review process conducted by the Audit Committee of the Board.
- Board change: Director Ronald Taylor will not stand for re-election and will retire at the 2026 Annual Meeting, expected November 18, 2026, and the filing says this is not due to any disagreement with the company.
- New lead director: Carol Burt, current Nominating and Governance Committee chair, will become Lead Director effective November 15, 2026.
- Background on Taylor: According to Exhibit 99.1, Taylor joined the Board in 2005 and served as Lead Director since 2013, with more than 21 years of service.
- Exhibits: The filing includes KPMG's letter to the SEC (Exhibit 16.1) and a press release dated August 17, 2026 (Exhibit 99.1).
03—Questions
Frequently Asked Questions
Why did ResMed change its independent auditor?
The filing says the Audit Committee performed a competitive review process to evaluate firms for the fiscal year ending June 30, 2027, and after completing it approved the dismissal of KPMG and the appointment of PwC. The filing does not state a specific reason beyond that review.
Did KPMG's audit reports contain any problems?
According to the filing, KPMG's reports on the consolidated financial statements for the fiscal years ended June 30, 2026 and 2025 contained no adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope, or accounting principles.
Is the PwC appointment final?
The appointment is subject to completion of PwC's standard client acceptance procedures, as stated in the filing.
Why is Ronald Taylor leaving the Board?
Taylor informed the Board on August 13, 2026 that he will not stand for election at the 2026 Annual Meeting and intends to retire effective at that meeting. The filing states his decision is not due to any disagreement with the company on any matter relating to its operations, policies or practices.
Who is replacing Taylor as Lead Director, and when does it take effect?
The Board appointed Carol Burt as Lead Director effective November 15, 2026. The press release in Exhibit 99.1 says Burt has served on the Board since 2013, chairs the Nominating and Governance Committee, and is also a member of the Audit Committee and the Compliance, Privacy and Quality Committee.
04—Continue